2 results about "Oncostatin M" patented technology

This invention relates to the field of biomedical technology, and in particular to mesenchymal stem cells, their preparation methods, and applications. The method for preparing mesenchymal stem cells includes the following steps: culturing the mesenchymal stem cells under hypoxic conditions with an oxygen volume fraction of 2%–4%, and during the hypoxic culture, pre-activating the mesenchymal stem cells by contacting them with an induction system containing 1–3 ng / mL Oncostatin M, 1–10 ng / mL IL-1β, and 2–10 ng / mL HMGB1 for 6–24 hours. Mesenchymal stem cells treated by this method can significantly inhibit lymphocyte proliferation, reduce the proportion of pro-inflammatory T cell subsets such as Th1 and Th17, increase the proportion of Treg cells, and effectively reduce the level of the inflammatory factor TNF-α.

The application discloses application of a compound specifically targeting onimstatin M in preparation of a medicine for resisting Pseudomonas aeruginosa infectious lung injury, relates to the technical field of biological medicine, and the compound plays a role in resisting Pseudomonas aeruginosa infectious lung injury through specific binding of onimstatin M protein; the compound can be specifically and stably combined at a key function site of the onimstatin M protein; the compound is used for reducing the content of TNF-alpha, IL6 and IL1beta in serum of an individual with lung injury caused by Pseudomonas aeruginosa infection; a medicine composition is provided, and the medicine composition comprises an effective amount of the compound and a pharmaceutically acceptable carrier; based on the new target of onimstatin M, an active medicine capable of effectively reducing lung injury is developed, and in particular, a compound overcoming the limitations of high cost and injection administration of an antibody medicine.